NCCN Guidelines for Patients® | Malignant Pleural Mesothelioma - page 56

56
NCCN Guidelines for Patients
®
: Malignant Pleural Mesothelioma
Version 1.2012
Index
Anxiety
30, 33
Asbestos
9, 11, 36
Biopsy
12–14, 17
Cancer cells
7, 9, 12, 13, 16, 20, 22, 24, 25, 27
Cancer spread
7
Cancer staging
16, 19, 20, 39
Chemotherapy
22, 24, 27
Chest wall
6, 17, 19, 29
Computed tomography
11–14, 16, 17, 22, 24–26, 29
Depression
30
Gene changes
7, 9
Lymph nodes
7, 16, 17, 19, 23
Magnetic resonance imaging
16, 17
Mediastinoscopy
16, 17
Member institutions
54, 55
Mesothelium
4, 6, 7, 14
National Comprehensive
Cancer Network
2, 51
Panel members
52, 53
Pleura
6, 9, 11, 13, 17, 19, 23, 29
Pleural biopsy
11, 13, 14, 17
Pleural cavity
6, 11, 12, 29
Pleural mesothelioma
7
Positron emission tomography
16, 29
Primary treatment
23
Radiation therapy
23–26, 29
Risk factors
9
Serum mesothelin-related peptide
11, 14
Supportive care
29, 30
Surgery
21–24
Extrapleural pneumonectomy
23, 24
Pleurectomy/decortication
23, 24
Symptoms
11, 29, 30, 33, 34
Tests
11–17, 21, 22
Diagnosis
11–14
Treatment planning
16, 17, 21, 33
Thoracentesis
11, 12
Treatment
21–27
Adjuvant
24, 25
Neoadjuvant
22
Primary
23
Treatment plan
32–34
Thoracoscopic biopsy
13, 14, 17
1...,46,47,48,49,50,51,52,53,54,55 57,58,59,60
Powered by FlippingBook